Infensa Bioscience

First-in-class drugs with addressable worldwide market of tens of millions of patients per year who suffer heart attack or stroke. Ability of a single drug class to address multiple diseases enables staged clinical development with continuous value creation. Other potential indications: traumatic head injury, hypoxic brain injury (cerebral palsy), retinal artery thrombosis, kidney artery thrombosis, cardiac and brain surgery, endarterectomy and heart valve replacement. Key asset protected by patents granted globally.